Bicalutamide Tablet, Film Coated
Product Images NDC 60429-177

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Bicalutamide (NDC 60429-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 177 01lb

60429 177 01lb
This is a medication with the National Drug Code (NDC) 60429-177-01, containing Bicalutamide USP 50mg in tablet form. The dosage information is available in the accompanying prescribing information, and it is important to keep the medication out of reach of children. The pharmacist should dispense the patient information along with the medication, which can be printed from https://gsms.us/. The medication should be stored at a controlled room temperature of 20°C-25°C. The manufacturer is Intas Pharmaceuticals Limited, and the medication is marketed by GSMS, Incorporated in Camarillo, CA, USA.*
FDA Label Image

Fig_1 (Bicalutamide Fig 1)

Fig_1 (Bicalutamide Fig 1)
This is a table showing four different values (0.3, 0.2, 0.1, 0.0) and two treatments (Bicalutamide plus LHRH-A, Flutamide plus LHRH-A) for a specific medical condition. The table also includes a list of days (365, 730, 1095, 1460, 1825) and a heading indicating "Days to death". However, without more context, it is difficult to determine exactly what the table represents or what the values mean.*
FDA Label Image

Fig_2 (Bicalutamide Fig 2)

Fig_2 (Bicalutamide Fig 2)
This appears to be a table or graph comparing two treatments for a medical condition using the drugs Bicalutamide and Flutamide in combination with LHRH agonists. The table shows the percentage of patients who did not experience disease progression over a period of up to 1825 days (5 years) on each treatment. However, without more context or a clear indication of what condition is being treated, this information is not very useful.*
FDA Label Image

Chem (Bicalutamide Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.